A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto
Y
Y
Department of Internal Medicine, Tohoku Kosei-Nenkin Hospital, Japan.
Hotta
N
N
Shigeta
Y
Y
Sakamoto
N
N
Kito
S
S
Matsuoka
K
K
Takahashi
A
A
Kikkawa
R
R
Sakuma
A
A
D000328:Adult; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D003929:Diabetic Neuropathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008475:Median Nerve / Q000187:drug effects / Q000503:physiopathology; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D010543:Peroneal Nerve / Q000187:drug effects / Q000503:physiopathology; D010919:Placebos; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D053778:Thiazolidines
D000449:Aldehyde Reductase; D006442:Glycated Hemoglobin; D010919:Placebos; D012236:Rhodanine; D053778:Thiazolidines; C038131:epalrestat